Which is better, MOTS-c or humanin?
Neither has evidence to support clinical use. MOTS-c is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), which is not an FDA approval, is not binding, and does not change its evidence grade; humanin has no lawful US route. Both sit at the animal only evidence grade, and the human data for each are association studies of natural blood levels or genetics rather than treatment trials. Humanin also carries a theoretical tumor survival concern from its anti-apoptotic action that has not been studied in people. [1] [2] [4] [7] [8] [9] [12]
How do MOTS-c and humanin compare?
| Dimension | MOTS-c | Humanin |
|---|---|---|
| Origin [1] [4] | 16 amino acids, encoded in the mitochondrial 12S rRNA gene. | 24 amino acids, encoded in the mitochondrial 16S rRNA gene (MT-RNR2). |
| Mechanism [1] [4] [5] | Inhibits the folate cycle and purine synthesis, raising AICAR and activating AMPK, which increases muscle glucose uptake and fat oxidation; moves to the nucleus under metabolic stress. | Binds Bax and IGFBP-3 inside cells to block apoptosis and signals through a CNTFR, WSX-1, and gp130 receptor complex that activates STAT3. |
| Strongest animal findings [1] [2] [4] [5] [7] | Prevented diet induced obesity and insulin resistance in mice (0.5 mg/kg daily) and improved running capacity in young and old mice (15 mg/kg). | Rescued neurons from Alzheimer's related death in culture, improved hepatic insulin sensitivity in rats, and the analog HNG improved metabolic healthspan and memory in middle aged mice without extending mean life span. |
| Human data [2] [3] [6] [7] | Blood and muscle levels rise acutely with exercise in 10 young men; a MOTS-c sequence variant is associated with type 2 diabetes in Japanese men. No treatment trial. | Higher plasma levels associated with preserved coronary endothelial function in 40 patients; levels decline with age and are higher in centenarian offspring. No treatment trial. |
| Theoretical safety concerns [1] [4] [5] | Possible added glucose lowering with diabetes drugs, extrapolated from mouse AMPK data. | Possible support of tumor cell survival from its anti-apoptotic, STAT3 activating action; possible added glucose lowering. |
| Note: Neither concern has been tested in people because no human safety data exist for either peptide. | ||
| FDA and compounding status [8] [9] [12] [13] | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). | Not identified on any 503A nomination list or PCAC agenda and not covered by HHS's October 2026 draft policy, so a 503A pharmacy has no federal basis to compound it as a bulk substance. |
| Access and cost [8] [9] [11] [12] | Only as a single-ingredient compounded product on a patient-specific prescription under HHS's October 28, 2026 draft enforcement discretion policy, if its conditions are met; it is not on the 503A bulks list. No verified compounded price yet. | No lawful channel. Only research chemical listings, whose products are unapproved drugs when sold for human use and are not verified for purity. |
| Animal study dose ranges [1] [2] [5] [7] | 0.5 mg/kg per day intraperitoneally (metabolic) up to 15 mg/kg (exercise) in mice. | 0.1 to 4 mg/kg intraperitoneally in rodents; 2 to 4 mg/kg HNG twice weekly in the mouse healthspan study. |
| Note: No human dose has been established for either peptide. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | MOTS-c | Humanin |
|---|---|---|
| Class | Mitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA | Mitochondrial derived peptide (24 amino acids) encoded in the 16S rRNA region of mitochondrial DNA |
| What it is | A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics. | A 24 amino acid peptide coded by mitochondrial DNA, protective in cells and rodents and tied to blood levels in people; no human treatment trials. |
| Evidence | Evidence: Animal-only evidence | Evidence: Animal-only evidence |
| FDA status | Regulatory: HHS interim policy (draft) | Regulatory: Unscheduled |
| Compounding | MOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. | Humanin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy has no federal basis to compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name for human use are unapproved drugs. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold), Intraperitoneal injection (animal studies) | Subcutaneous injection (as sold), Intraperitoneal and intracerebroventricular injection (animal studies) |
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has MOTS-c been tested directly against humanin?
No published trial has compared MOTS-c and humanin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do MOTS-c and humanin cost?
| Dimension | MOTS-c | Humanin |
|---|---|---|
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | MOTS-c price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the MOTS-c page and the Humanin page.
Frequently asked questions
Which is better for longevity, MOTS-c or humanin?
Neither has been shown to extend life or healthspan in people. In mice, MOTS-c improved physical capacity in old animals and the humanin analog HNG improved metabolic healthspan and memory without extending mean life span. Human data for both are limited to blood level associations. [2] [7]
Are MOTS-c and humanin the same kind of peptide?
Yes, both are mitochondrial derived peptides translated from short reading frames inside mitochondrial ribosomal RNA genes, but from different genes (12S for MOTS-c, 16S for humanin) and with different mechanisms: MOTS-c works through AMPK and metabolism, humanin through anti-apoptotic and STAT3 signaling. [1] [4] [5]
Can I get a prescription for either one?
MOTS-c possibly, under conditions; humanin, no. MOTS-c is not FDA approved or on the 503A bulks list, but it is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Humanin has never been nominated, is not covered, and has no lawful US route. State law still applies. [8] [9] [12] [13]
Are they allowed in sport?
No. Both are prohibited at all times: MOTS-c is named under WADA section S4.4 as a metabolic modulator, and humanin falls under section S0 as a non-approved substance. [10]
Does humanin protect against Alzheimer's disease?
Humanin was discovered because it protected cultured neurons from damage caused by Alzheimer's related genes and amyloid beta, but that work was in cells. No human trial has tested humanin or an analog for Alzheimer's disease or cognition. [4] [7]
Conditions studied
From the blog
- MOTS-c side effects and benefits: what the evidence shows
No published human study has reported MOTS-c side effects, because none has given it to people and posted results. The mouse benefit claims, the safety gaps FDA named, and its legal status.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
- [2]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
- [3]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
- [4]Hashimoto Y et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A 2001PubMed 11371646, 2001
- [5]Muzumdar RH et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One 2009PubMed 19623253, 2009
- [6]Widmer RJ et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol 2013PubMed 23220334, 2013
- [7]Yen K et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 2020PubMed 32575074, 2020
- [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA
- [10]WADA Prohibited List (section S0 non-approved substances and section S4.4 metabolic modulators)WADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). MOTS-c vs humanin: evidence, cost, and legality. https://peptideagent.ai/compare/mots-c-vs-humanin- HTML link
<a href="https://peptideagent.ai/compare/mots-c-vs-humanin">MOTS-c vs humanin: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.